Pediatric Primary Care Case Studies (137 page)

abuse situations,
193
–206

case presentation for,
193
–198,
200
,
204

diagnosis of,
193
–200

drawings as indicators,
201

interviews,
193
–199

physical examinations,
199
–200

risk factors,
193
–195

signs/symptoms reviews,
202
–203

epidemiology/etiology of,
193
–195

fundamental contexts of,
193
–195,
205

management of,
203
–204

abuse consequences,
204

therapeutic plans,
203
–204

objectives for,
193

reporting of,
194
–200,
203

resources for,
205
–206

Accutane.
See
isotretinoin (Accutane)

ACE (angiotensin-converting enzyme) inhibitors,
280

acne (adolescents),
467
–480

case presentation for,
467
–468,
470
,
479

diagnosis of,
469
–471

diagnostic testing,
471

differential,
469
–470

history-taking,
469
–470

physical examination,
470

epidemiology/etiology of,
468
–469

cultural/ethnic factors,
469

pathophysiology,
468

fundamental contexts of,
467
–468,
479

management of,
471
–479

care plan,
478
t

education plan,
473
–474

follow-up visits,
479

iPLEDGE program,
473

medications,
472
–473,
474
t–478t

therapeutic plans,
471
–473

objectives for,
467

resources for,
479
–480

ACS (American Cancer Society)

cervical cancer detection guidelines,
444

Pap smear recommendations,
428

acute lymphoblastic leukemia.
See
ALL (acute lymphoblastic leukemia)

acute
vs
. chronic diarrhea,
391
–392.
See also
diarrhea/vomiting

acyclovir,
463

AD (atopic dermatitis),
455
–466

case presentation for,
455
,
457
–458,
459
,
463
–464

diagnosis of,
456
–459

differential,
459

history-taking,
459

physical examination,
456

epidemiology/etiology of,
456
–457

fundamental contexts of,
455
–456

management of,
459
–464

antibiotics,
462
–463

antivirals,
463

Atopiclair,
463

follow-up visits for,
463
–464

medications,
460
–463,
461
t

MimyX for,
463

parental/patient education for,
463
–464

PUVA therapy for,
462

RAST/SPT,
458

systemic steroids for,
462

TCIs for,
462

topical corticosteroids for,
460
–462,
461
t

triggers of,
458
–459

objectives for,
455

resources for,
465
–466

AD (autism disorder),
28
,
30
f

adapalene (Differin),
474
t–477t

adenovirus,
378
,
388

ADHD (attention deficit hyperactivity disorder),
175
–192

case presentation for,
176
,
178
,
180
,
186
,
189
–190

diagnosis of,
176
–181

AAP guidelines,
178
–179

comorbidities,
179
–180,
179
t

Conners’ Scales,
180
–181

diagnostic testing,
180
–181

differential,
179
t

DSM-IV-TR
criteria,
176
–178,
177
t–178t

physical examinations,
180

Vanderbilt assessment,
180
–181

fundamental contexts of,
175
,
191

management of,
182
–190

appetite and,
188

cardiac problems and,
187
–188

family education,
182

follow-up visits,
189
–190

medications,
182
–187,
183
t–185t

sample approach,
187
t

sleep disturbances and,
188
–189

objectives for,
175

prognosis for,
190

resources for,
191
–192

adolescent-specific concerns

acne,
467
–480

birth control,
427
–440

depression,
207
–220

diagnostic reasoning for,
1
–8

fatigue,
59
–72

late-preterm infants (adolescent parents),
493
–506

LGBT issues,
221
–231

PPEs,
133
–163

vaginal discharge,
441
–454

aeroallergens,
458
–459

albuterol,
260

ALL (acute lymphoblastic leukemia),
486
–487

Allegra.
See
fexofenadine (Allegra)

alpha-glucosidase inhibitors,
278

Alpha Keri soap,
460

American Academy of Neurology Practice Parameters,
330

American Academy of Child and Adolescent Psychiatry,
65

American Academy of Dermatology,
472
–473